We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Warns Lymol Medical for Failing Postmarketing Step
FDA Warns Lymol Medical for Failing Postmarketing Step
The FDA issued a warning to Lymol Medical for failing to submit a final postmarketing requirement (PMR) report on its sterile talc product without providing a good explanation for the delay.